ADMA Biologics Inc vs Teucrium Soybean Fund — how do they compare? ADMA Biologics Inc trades at $9.81 (market cap $2.22B), while Teucrium Soybean Fund trades at $24.82. The key difference: Teucrium Soybean Fund is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | SOYB | |
|---|---|---|
Market Cap | $2.22B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $20.38 | $26.28 |
52-Week Low | $7.60 | $21.46 |
Enterprise Value | $2.29B | — |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.
Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.
SOYB trades at $25.04, showing minimal daily change of 0.03%. Technical indicators suggest a bearish bias with moving averages signaling caution, though oscillators are neutral. Recent news highlights potential agricultural sector tailwinds from China's $17 billion crop purchase pledge through 2028, which could benefit U.S. exporters like SOYB. However, key financial ratios including P/E, P/S, and profitability metrics are currently unavailable, limiting fundamental clarity.
The stock faces near-term technical headwinds but may find support from positive agricultural trade developments. Investment opportunity hinges on improved financial disclosure and sector momentum, while risks include geopolitical tensions and lack of transparent fundamentals. Investors require updated earnings reports to assess valuation properly.
Trailing returns across standard periods
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →SOYB is a commodity ETF that provides exposure to the price of soybean futures. It utilizes a laddered strategy by investing in several benchmark futures contracts to reduce the impact of roll costs and contango in the agricultural market.
Read more on SOYB →